Quick Answer
Anika Therapeutics, Inc. reported Net Income of -$10.88 million for fiscal year 2025.
Anika Therapeutics, Inc. Net Income — Annual History
| Fiscal Year | Net Income | YoY Change |
|---|---|---|
| 2025 | -$10.88M | +80.7% |
| 2024 | -$56.38M | +31.8% |
| 2023 | -$82.67M | -456.3% |
| 2022 | -$14.86M | -459.4% |
| 2021 | $4.13M | +117.2% |
| 2020 | -$23.98M | -188.2% |
| 2019 | $27.19M | +45.2% |
| 2018 | $18.72M | -41.2% |
| 2017 | $31.82M | -2.2% |
| 2016 | $32.55M | +5.8% |
| 2015 | $30.76M | -19.7% |
| 2014 | $38.32M | +86.2% |
| 2013 | $20.57M | +75.0% |
| 2012 | $11.76M | +38.9% |
| 2011 | $8.47M | +96.2% |
| 2010 | $4.32M | +17.0% |
| 2009 | $3.69M | — |
Quarterly Net Income
| Quarter Ending | Net Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$2.33M | +92.2% | +41.3% |
| June 30, 2025 | -$3.97M | -4411.4% | +18.5% |
| March 31, 2025 | -$4.87M | -8.0% | +83.7% |
| September 30, 2024 | -$29.92M | -355.0% | -33897.7% |
| June 30, 2024 | -$88.0K | +96.8% | +98.1% |
| March 31, 2024 | -$4.51M | +56.4% | +31.4% |
| September 30, 2023 | -$6.58M | -57.5% | -139.9% |
| June 30, 2023 | -$2.74M | +3.6% | +73.5% |
- Anika Therapeutics, Inc. showed an increase of +80.7% in Net Income compared to the prior fiscal year.
- Over the 2009–2025 period, Anika Therapeutics, Inc.’s net income has declined by 395.0% (from $3.69 million to -$10.88 million).
- The most recent figure is from Anika Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 3, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: